Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

Company Growth (employees)
Gaithersburg, US
Size (employees)
1,098 (est)
Emergent Biosolutions was founded in 1998 and is headquartered in Gaithersburg, US

Emergent Biosolutions Office Locations

Emergent Biosolutions has offices in Gaithersburg, Washington, Lansing, Winnipeg and in 5 other locations
Gaithersburg, US (HQ)
400 400 Professional Dr
Baltimore, US
1111 S Paca St
Seattle, US
1050 2401 4th Ave
Richmond, GB
Kew Rd
Baltimore, US
5901 E Lombard St
Hattiesburg, US
46 Shelby Thames Dr
Show all (10)

Emergent Biosolutions Data and Metrics

Emergent Biosolutions Financial Metrics

Emergent Biosolutions's revenue was reported to be $116.9 m in Q1, 2017

Revenue (Q1, 2017)

116.9 m

Net income (Q1, 2017)

10.5 m

EBIT (Q1, 2017)

14.9 m

Market capitalization (21-Sep-2017)

1.9 b

Cash (31-Mar-2017)

270.2 m
Emergent Biosolutions's current market capitalization is $1.9 b.
USDFY, 2014FY, 2015FY, 2016


404.5 m489.3 m488.8 m

Revenue growth, %


R&D expense

108.3 m

General and administrative expense

143.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


110.3 m138 m63.6 m126.1 m164.9 m111 m101.5 m142.9 m116.9 m

R&D expense

37.4 m44.2 m38.7 m40.9 m41.9 m34.2 m35.3 m27.2 m20.5 m

General and administrative expense

30.6 m30.3 m34.5 m36.5 m31.6 m39.8 m44.1 m40.7 m35.2 m

Operating expense total

68 m74.5 m73.2 m77.4 m73.4 m73.9 m79.5 m67.9 m55.6 m
USDFY, 2014FY, 2015FY, 2016


280.5 m312.8 m271.5 m

Accounts Receivable

58.8 m120.8 m138.5 m


65.7 m76.9 m74 m

Current Assets

432.2 m538.6 m510.2 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


214.8 m308.7 m341 m333.4 m298.9 m270.2 m

Accounts Receivable

99.7 m57 m69.6 m66.7 m69.6 m128.1 m


84.7 m80.1 m88.2 m96.7 m81.2 m70.7 m

Current Assets

435.5 m473.5 m528.2 m528 m480 m489.2 m
USDFY, 2014FY, 2015FY, 2016

Net Income

36.7 m62.9 m51.8 m

Accounts Receivable

21.4 m(64 m)(22.4 m)


4.2 m(11.3 m)(9 m)

Accounts Payable

(9.3 m)4.7 m(14.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.2 m)6.6 m(21.5 m)(7.4 m)29.5 m4 m(7 m)14.4 m10.5 m

Depreciation and Amortization

15.3 m24.3 m8.5 m17.3 m25.9 m8.8 m17.8 m28.2 m10.2 m

Accounts Receivable

2.3 m36.1 m(5.2 m)(40.9 m)1.7 m51.2 m53.9 m45 m10.6 m


1.2 m4.7 m(16.5 m)(19 m)(14.4 m)(11.3 m)(19.7 m)(16.2 m)3.3 m
USDY, 2017


106.4 k

Financial Leverage

1.6 x
Show all financial metrics

Emergent Biosolutions Market Value History

Traffic Overview of Emergent Biosolutions

Emergent Biosolutions Online and Social Media Presence

Emergent Biosolutions News and Updates

BRIEF-Emergent Biosolutions to repurchase shares for up to $50 mln

* Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock

BRIEF-Emergent BioSolutions' board approves spin-off of Aptevo Therapeutics

* Emergent Biosolutions' Board Of Directors Approves Spin Off of Aptevo Therapeutics and sets record and dividend distribution dates and distribution ratio

BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55

* FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016

Emergent Biosolutions Company Life and Culture

You may also be interested in